Olema Oncology could be a standout player in developing therapies for women's cancers, particularly in breast cancer, according to Citi Research.
The stock was flat in trading on Tuesday, but has fallen more than 16% so far this year.
Last year, Olema shares soared more than 470% as the company released a series of positive updates, particularly about its lead investigational oncology drug palazestrant , Nochomovitz said.
"We believe palazestrant has emerged as a highly promising CERAN/SERD with opportunities across multiple lines of ER+ breast cancer," Nochomovitz wrote in a Tuesday note.
CDK4/6 inhibitors are drugs that are used to treat metastatic breast cancer, or advanced stage IV breast cancer, which has spread to other organs in the body far from the breast.
Persons:
Yigal Nochomovitz, Olema, Nochomovitz, Palazestrant, palazestrant, ribociclib
Organizations:
Oncology, Citi Research, FDA